NRSN: NeuroSense Therapeutics Earnings per share for the last twelve months
The TTM net income per share on the GURU.Markets time chart reflects the price action of NeuroSense Therapeutics (NRSN), a biopharmaceutical developer of ALS therapies investing in RNA regulation. The business model relies on outsourcing production and trials to minimize capital expenditures. The value of 0.00 shapes the current metric, while the cohesive management team led by Alon Ben-Nun prepares the final test results for publication.
Financial and market metric breakdowns for NeuroSense Therapeutics Ltd (NRSN)
- current quotes and average value forecast:
- market capitalization information:
- shareholders' equity book value data:
- debt and liquidity details:
Debt to Equity NeuroSense Therapeutics|NRSN - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity NeuroSense Therapeutics, Ltd.|NRSN - Company Total Debt Obligations|Debts to Book Capitalization NeuroSense Therapeutics Ltd.|NRSN - Long-Term Debt|Company Current Liabilities NeuroSense Therapeutics|Quick Liquidity Indicator neurosense-tx.com
- earnings and multiples data:
NRSN - Profit After Payment of Taxes|Projected Future Earnings NeuroSense Therapeutics|NRSN - Company Value to Net Income|Forward P/E Multiple NeuroSense Therapeutics, Ltd.|NRSN - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd.|NRSN - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) NeuroSense Therapeutics|NRSN - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months neurosense-tx.com|NRSN - Earnings per share trend in current year|Earnings growth forecast for next year NeuroSense Therapeutics
Fundamental company analysis:neurosense-tx.com (NRSN)
NeuroSense Therapeutics (NRSN) focuses on developing therapies for amyotrophic lateral sclerosis, leveraging a highly qualified scientific staff. This indicator calculates the total annual net income divided by the total number of shares, neutralizing the effect of equity dilution. It is critical for investors to track this metric to assess the real business efficiency relative to market value. The trend of this metric allows for the timely detection of how borrowing costs impact capitalization. Analyzing the rolling year earnings per share helps avoid investment stagnation.
Main competitors
BIIB - Earnings per share for the last twelve months|Earnings per share for the trailing year NBIX (neurocrine.com)|Regencell Bioscience Holdings Limited (RGC) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Axsome (AXSM)|Earnings per share for the last twelve months ACADIA Pharmaceuticals Inc|Xenon Corp (XENE) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) VKTX|SUPN - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Catalyst Pharmaceuticals, Inc. CPRX|DNLI: Earnings per share for the last 12 months|HRMY - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Biohaven Corp BHVN|AMLX: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months trevitherapeutics.com (TRVI)|Net earnings per share for the last 12 months PRAX|AVXL: Earnings per share for the trailing year|Net earnings per share for the last 12 months CBLL (CeriBell Corp)|Earnings per share for the last four quarters PRTA|Net earnings per share (EPS TTM) ALEC (Alector)|Earnings per share for the trailing year ANNX|Omeros Corp. - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Neurogene Inc|AC Immune Corp (ACIU) - Earnings per share for the last twelve months|Voyager Corp - Earnings per share for the trailing year|NMRA (Neumora Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) scilexholding.com|Earnings per share for the last twelve months Tevogen Bio (TVGN)|ACOG: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) CGTX (Cognition Therapeutics)|Inhibikase Pharma (IKT) - Net earnings per one share for the last twelve months|SAVA: Net earnings per share for the last 12 months|ASRT - Net earnings per share (EPS TTM)|COYA (coyatherapeutics.com) - Net earnings per share for the last 12 months|VTGN: Earnings per share for the last four quarters|OVID (Ovid Therapeutics Inc) - Net earnings per share (EPS TTM)|Acumen Pharmaceuticals, Inc (ABOS) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) CRVO|Net earnings per share for the last 12 months alteritytherapeutics.com ATHE|Earnings per share for the last twelve months Clene CLNN|Net earnings per share for the last four quarters PepGen Inc (PEPG)|JUNS - Earnings per share for the last twelve months|RLMD (Relmada Corp) - Earnings per share for the last 12 months|Annovis Bio, Inc. (ANVS) - Earnings per share for the last twelve months|Grace Therapeutics - Earnings per share for the trailing year|Earnings per share for the last twelve months Firefly Neuroscience|ANEW Medical, Inc. (KLTO) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Reviva Pharmaceuticals Holdings (RVPH)|metaviatx.com - Earnings per share for the last 12 months|Earnings per share for the last twelve months NeurAxis, Inc. NRXS|HSDT: Earnings per share for the last 12 months|Passage Bio Corp - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Neuphoria Therapeutics Inc.|NERV (Minerva Neurosciences Corp) - Net earnings per share for the last 12 months|Athira Pharma Corp (ATHA) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Addex Therapeutics|ALZN: Earnings per share for the trailing year|Earnings per share for the last twelve months Cyclerion Therapeutics (CYCN)|PTIX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Pasithea Therapeutics Corp. KTTA|CRGT: Earnings per share for the last 12 months|Avenue Therapeutics - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months brainstorm-cell.com|CARA (Cara Therapeutics) - Net earnings per share for the last 12 months|Chromocell Therapeutics Corp (CHRO) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Eliem Therapeutics, Inc.|ITCI: Earnings per share for the trailing year|Earnings per share for the last twelve months Longboard Pharmaceuticals (LBPH)|MRNS - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months NKGen Biotech NKGN|Net earnings per share for the last four quarters NeuroBo Pharmaceuticals Inc (NRBO)|Sage Therapeutics, Inc - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Synaptogenix, Inc|Trevena, Inc. (TRVN) - Earnings per share for the last twelve months|Earnings per share for the last 12 months VIGL|Earnings per share for the last twelve months Anew Medical|Cerevel Therapeutics Inc (CERE) - Net earnings per share for the last four quarters
